Skip to main content
Premium Trial:

Request an Annual Quote

Varian: Phil Febbo

Varian has appointed Phil Febbo to its board of directors. Febbo currently serves as chief medical officer at Illumina as well as on the board of the American College of Medical Genetics and Genomics Foundation. Prior to joining Illumina, he served as CMO at Genomic Health. Before working at Genomic Health, Febbo was a professor of medicine and urology at the University of California, San Francisco. 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.